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Abstract
Background: The link between type 1 diabetes and thyroid autoimmunity is well described. The same cannot be
said for type 2 diabetes where results have been mixed so far. We investigated the prevalence and determinants of
thyroid autoimmunity among Ghanaian type 2 diabetes patients.
Methods: This was a case-control study involving 302 type 2 diabetes patients and 310 non - diabetic controls
aged 40–80 years. Anthropometric and blood pressure measurements were obtained. Fasting samples were
analyzed for glucose, thyroid function, and antibodies to thyroglobulin and thyroid peroxidase.
Results: The prevalence of thyroid autoimmunity was significantly higher among T2DM subjects (12.2% vs. 3.9%, p = 0.
0004). Among T2DM subjects, 44 (14.7%) tested positive for TPOAb, 5 (1.7%) tested positive for TGAb and 15 (5.0%)
tested positive for both autoantibodies. Females T2DM subjects showed a 3-fold increased risk of thyroid
autoimmunity compared to males (OR:3.16, p =0.004), T2DM subjects with hyperthyroidism had a 41% increased risk of
thyroid autoimmunity (OR: 1.41, p < 0.001), sub-clinical hyperthyroidism increased the risk of thyroid autoimmunity by 2
fold, (OR:2.19, p < 0.001), subclinical hypothyroidism increased the risk of autoimmunity by 4-fold, (OR:3.57 95% p < 0.
0001), and hypothyroidism was associated with a 61% increased risk of thyroid autoimmunity (OR: 1.61,1.35–2.23).
Dyslipidaemia was associated with a 44% increased risk of thyroid autoimmunity (OR: 1.44, p = 0.01) and a percentage
increase in HbA1c was associated with 46% increased risk of thyroid autoimmunity (OR:1.46, p < 0.0001).
Conclusion: We observed a high prevalence of thyroid autoimmunity in Ghanaian T2DM subjects compared to the
general population. Thyroid autoimmunity in T2DM subjects was significantly associated with female gender, thyroid
dysfunction, dyslipidaemia and poor glycemic control.
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Background
Diabetes and thyroid disorders represent the two com-
monest endocrinological conditions seen in adult medical
practice [1, 2]. The concurrence of the two conditions in
the same individual can prove inimical to achieving good
glycemic control and further multiply the cardiovascular
risk associated with diabetes. [1, 2] Studies worldwide have
shown a higher prevalence of thyroid dysfunction in type
2 diabetes (T2DM) patients and vice-versa [2–8]. The
spectrum of thyroid disorders (like diabetes) is wide; and
it is continuously experiencing a change in epidemiology,
usually determined by iodine levels seen in the population
in focus [9, 10]. In arears of the world where intake of iod-
ine, a major component of thyroid hormones, is sufficient,
autoimmune disorders represent the commonest cause of
thyroid pathology [11]. In contrast, there is widespread
dietary iodine deficiency in Africa, which underlines most
of the clinical and pathological presentations of thyroid
disease [12]. Recently, with the remarkable improvement
in iodine nutrition through widespread salt iodination on
the continent, there appears to be a shift in thyroid
epidemiology towards autoimmunity [13]. Thyroid
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autoimmunity which comprises a number of distinct but
pathogenically related immune-mediated destructive dis-
orders of the thyroid gland is often characterized by the
presence of autoantibodies directed mostly against thyroid
peroxidase (TPOAb) and thyroglobulin(TGAb) [14]. Type
1 diabetes has an established association with auto-
immune thyroid disorders through a common genetic in-
heritance [15, 16]. Studies to investigate a link between
thyroid autoimmunity and T2DM have produced mixed
results so far, mostly beset by differing methodologies, iod-
ine statuses and sensitivities of immunological tests
employed in determining thyroid autoantibodies [17–21].
Whiles Akbar et al. [4] obtained a significantly higher
prevalence of thyroid autoimmunity in the study of Saudi
T2DM subjects, Afkhami- Ardekani et al. [22] study of
Iranian T2DM subjects did not yield any significant differ-
ence between the two groups. Among Africans, there exist
a gaping hole of literature documenting thyroid auto-
immunity both among the general population and T2DM
patients. Cardoso et al. in one of the few studies on the
continent to date, compared type 1 diabetes patients and
controls with T2DM subjects for thyroid autoantibodies
and obtained a predictably low autoantibody level of 1.7%
among T2DM subjects [23]. As far as we are aware, no re-
cent published studies were cited on the topic on the con-
tinent to reflect the changing epidemiology of thyroid
diseases among Africans toward increased autoimmunity.
The aim of this study was therefore to determine the
prevalence and the associated factors of thyroid auto-
immunity in Ghanaian T2DM patients.
Methods
This was a case-control study in which cases were con-
secutive patients with established T2DM defined by the
WHO criteria [18], self-reported diagnosis of diabetes
and/or treatment with antidiabetic medications (among
patients who were insulin non-requiring in the first year
after diagnosis for glycemic control). Cases were re-
cruited from the outpatient diabetes clinic of Komfo
Anokye Teaching Hospital (KATH), the second largest
tertiary referral hospital in Ghana from April 2014 to
April 2015. Community in-dwelling age and sex
matched adults from the same region were recruited to
serve as controls after normoglycemia was documented
by both fasting plasma glucose (FPG) and glycated
hemoglobin (HbA1c). Using a structured validated ques-
tionnaire and a review of medical records we obtained
the sociodemographic and clinical information of all par-
ticipants. Because of their confounding effects on thy-
roid function, we excluded pregnant women, patients on
amiodarone, lithium and long-term corticosteroids as
well as those with an acute illness and history of
hospitalization less than 6 months from the day of
recruitment.
Ethical approval and consent to participate
The study was approved by the Committee for Human
Research Publications and Ethics at the School of Medical
Sciences, Kwame Nkrumah University of Science and
Technology and the Komfo Anokye Teaching Hospital,
Kumasi. All participants gave an informed consent with




Body weight and height were taken in duplicates using
a combined manual scale and stadiometer (Asimed
MB 211 T plus Asparatos Y Sistemas de Medida,).
Body mass Index (BMI) was calculated as weight in
kilogram divided by the square of height in meters
(kg/m2). Overweight/general obesity was defined as
BMI ≥25 kg/m2 [17].
Waist circumference measurement
Duplicate waist circumference (WC) measurements
were taken and the average recorded for both group of
participants, WC measurements > 80 cm and 94 cm
were recorded as central obesity for females and males
respectively [16].
Blood pressure measurement
Duplicate blood pressure recordings were taken with the
participant in a seated upright position using a standard
mercury sphygmomanometer after at least 15 min of
rest. Hypertension was defined as mean blood pressure ≥
140/90 mm Hg and/ or documented antihypertensive
therapy [19].
Smokers were identified by self-report as those who
had smoked at least 10 sticks of cigarette per day for
6 months or more or those who smoked daily for 1 year
or more regardless of the number of cigarettes smoked
per day [20]. Positive alcohol intake status was identified
when greater than 14 units of alcohol was consumed per
week in the case of a female and 21 units per week in
case of a male [21].
Laboratory measurements
Approximately ten milliliters (10mls) of fasting venous
samples were collected from each participant into
vacutainer tubes (Becton Dickinson, Rutherford, and
N.J) and Sequestrene bottles. Samples were manually
processed and cryopreserved before transporting to
laboratory for analysis. Fasting plasma glucose (FPG),
thyroid profile: free thyroxine (FT4), free triiodothyr-
onine (FT3), thyroid stimulating hormone (TSH), total
cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-
C), triglycerides (TG)], urea, creatinine, TGAb and
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TPOAb were assayed by Chemoimmunoluminiscence
method (Roche Diagnostics, Cobas e411 automated
immunoassay analyzer, Indianapolis, USA) following
the manufacturer’s instructions. Glycated hemoglobin
(HbA1c) measurements were performed by standard-
ized high performance liquid chromatography assay
using Bio-Rad Variant II hemoglobin testing autoana-
lyzer. The reference range, intra-assay and interassay
coefficients of variation for thyroid hormones and
antibodies were as follows:
(TSH: O.25–5.0 IU/ml, <2.1% and <2.4%, FT3: 3.7–
10.4pmol/l, 5.8% and 6.9% for FT3, FT4: 7.5–21.1pmol/l,
2.8% and 2.4%, TPOAb > 5.6 U/L, 2.1% and 6.1%,
TGAb > 4.1U/L, 1.9% and 5.6%).
Thyroid function was classified as: Euthyroidism -
when FT4, FT3 and TSH were within the normal range,
hypothyroidism when TSH level was greater than the
upper limit of the reference range and FT4/ or FT3 is
lower than the lower limit of their reference ranges,
Subclinical hypothyroidism- when TSH is greater than
the upper limit of the reference range and FT4 and FT3
are within the normal range. Hyperthyroidism- when
TSH level is lower than the upper limit of the reference
range and FT4/or FT3 is greater than the upper limit of
their reference ranges, subclinical hyperthyroidism-
when TSH level is lower than the lower limit of the ref-
erence range and FT3 and FT4 are within the normal
range. Thyroid autoimmunity was defined as positive
TPOAb and/or TGAb.
Dyslipidemia was defined as TG level ≥3.0 mmol/L
and HDL cholesterol level (<1.0 mmol/L) regardless of
patient’s gender [24].
Statistical analysis
Data was analyzed using Graph Pad Prism 7 software for
Mac OS X. Continuous and dichotomous variables were
presented as mean (standard deviation) and n (%) re-
spectively. Data normality assumption was performed by
visual inspection of distribution as well as D Agostino
and Pearson Omnibus normality test. Statistical differ-
ence between means, medians and proportions were
assessed using student t-tests, Mann-Whitney U tests
and chi-square test respectively. To adjust for the effects
of confounders, logistic regression models was carried
out to identify independent predictors of thyroid auto-
immunity. A significant level of P < 0.05 was used for the
analysis.
Results and discussion
Baseline characteristics of T2DM subjects and controls
The overall study population was 612 (comprising 302
T2DM subjects and 310 controls). Table 1 describes the
baseline characteristics of T2DM subjects and controls.
There was no difference in age (57.6 ± 9.4 vs. 57.2 ± 9.5,
p = 0.65) and percentage of females (58.9 vs 58.4, p =
0.95) between the 2 groups of participants. Type 2 dia-
betes subjects had significantly higher mean systolic
blood pressure (148.2 ± 20.5 vs. 130.4 ± 22.7, p < 0.0001),
mean diastolic blood pressure (82.6 ± 12.6 vs. 77.6 ± 12.7,
p < 0.0001), median BMI [27.9 (21.5–31.5) vs. 27.0 (24–
30.3, p = 0.03)], waist circumference [98 (90–106) vs. 94
(84–100.8) p < 0.0001] and proportion with dyslipidemia
(53% vs. 11%, p < 0.0001) compared to controls. The
proportion of participants that smoked or drank alcohol
was not significantly different between the two groups.
Prevalence of thyroid dysfunction and autoimmunity
between the two groups
As shown in Table 1, the prevalence of thyroid dys-
function between the two groups was not significant
(18.5 vs. 12.9, p = 0.06). The prevalence of thyroid
autoimmunity among T2DM participants was about 5-
fold higher than in controls (21% vs 4%, p < 0.0001).
Of the 302 T2DM subjects, 14.7% (n = 44) tested posi-
tive for TPOAb, 1.7% (n = 5) for TGAb and 5% (n =
15) for both antibodies. For controls 2% (n = 6), 1% (n
= 3) and 1% (n = 3) tested positive for TPOAb, TGAb
and both antibodies respectively. Significant difference
existed in the two groups in the prevalence of TPOAb
(14.7% vs 1.9, p < 0.0001), TPOAb and TGAb (5.0% vs
0.9%, p = 0.004). The difference in prevalence of TGAb
between the two groups was not significant (1.7% vs
0.9%, p = 0.95).
Figure 1 shows that the median concentration of
TPOAb was significantly higher in T2DM patients com-
pared to controls [4.5(2.9–6.3) vs 2.0(1.2–3.6), p <
0.0001]. The median concentration of TGAb was not
significantly different between the groups [2.4 (1.8–2.8)
vs 2.3 (1.6–2.8), p = 0.95].
Frequency of thyroid thyroid dysfunction among
autoimmunity positive participants
Figure 2 shows the frequency of thyroid dysfunction
among autoimmune positive participants. Of the 44
T2DM subjects who tested positive for TPOAb, 68%
(n = 30) had thyroid dysfunction, 20% (n = 1) of the 5
patients who tested positive for TGAb had thyroid dys-
function whiles 93% (n = 14) of the 15 patients with both
antibodies had thyroid dysfunction. Among controls,
17% (n = 1) of TPOAb positive had thyroid dysfunction,
20% (n = 1) of those with TGAb and TPOAb had thyroid
dysfunction. The presence of TPOAb and both anti-
bodies was significantly associated with thyroid dysfunc-
tion in T2DM subjects compared to controls. The
difference in the proportion of TGAb positive partici-
pants with thyroid dysfunction was not significant be-
tween the two groups.
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Clinical and laboratory characteristics of T2DM subjects
according to autoantibody status
As shown in Table 2, T2DM subjects with thyroid auto-
immunity had significantly higher FPG [9.7 (8.7–11.2
VS. 7.6 (6.7–9.4), p <0.0001], HbA1c [8.2 (6.8–9.8) vs.
6.1 (5.2–9.6) p <0.0001], TC [6.03 (4.7–7.06) vs. 4.9
(3.9–5.7), p < 0.0001], LDL-C [3.87 (2.83–5.08) vs. 2.90
(2.0–3.60), p < 0.0001] and TSH [3.4 (0.1–8.1) vs
1.1(0.8–1.8) p < 0.04] compared to T2DM subjects with-
out thyroid autoimmunity. There was no significant
difference between the two groups in terms of age, dur-
ation of diabetes, blood pressure and renal function.
Associations of thyroid autoimmunity in T2DM subjects
The results of multiple logistic regression analysis are
shown in Table 3 were as follows; after adjusting for
BMI, T2DM subjects with thyroid autoimmunity had
a 3-fold increased risk of being females, (OR: 3.16
95% CI: 1.46–6.87, p < 0.0001), a percentage increase
in HbA1c increased the odds of thyroid autoimmunity
by 46% (OR: 1.46 95% CI 1.23–1.73) and a mmol in-
crease in TC increased the odds of thyroid auto-
immunity by 44%. The odds of thyroid dysfunction
Fig. 2 Thyroid dysfunction in autoantibody positive T2DM subjects
and Controls
Fig. 1 Mean concentration of thyroid autoantibodies in
study participants
Table 1 Demographic and Clinical Characteristics of Study participants
Variable T2DM subjects Controls P- Value
Number 302 310
Age, years (mean ± SD) 57.6 ± 9.4 57.2 ± 9.5 0.65
Hypertension, n(%) 213 (70.5) 75 (24.5) <0.0001
Female gender, n (%) 178 (58.9) 181 (58.4) 0.95
SBP, mmHg (mean ± SD) 148.2 ± 20.5 130.4 ± 22.7 <0.0001
DBP, mmHg (Mean ± SD) 82.6 ± 12.6 77.6 ± 12.7 <0.0001
Dyslipidemia, n (%) 159 (52.6) 24 (11.4) <0.0001
Alcohol, n (%) 87 (28.8) 120 (29.0) 0.96
Smoking, n (%) 22 (7.3) 15 (4.8) 0.24
Body mass index, kg/m2, median (IQR) 27.9 (21.5–31.5) 27.0 (24–30.3) 0.03
Waist Circumference, cm, median (IQR) 98 (90–106) 94 (84–100.8) <0.0001
Central obesity, n (%) 210 (69.5) 121 (39.0) <0.0001
HbA1c,%, median (IQR) 8.2 (6.9–9.6) 5.2 (5.0–5.4) <0.0001
Fasting blood glucose, mmol/L, (Mean ± SD) 10.4 ± 5.4 5.3 ± 1.4 <0.0001
Creatinine,μmol/L, median (IQR) 84 (62–106.8) 77 (63–99) 0.21
Thyroid dysfunction, n (%) 56 (18.5) 40 (12.9) 0.06
Thyroid autoimmunity, n (%) 64 (21.2) 12 (3.9) <0.0001
Positive TPOAb, n (%) 44 (14.7) 6 (1.9) <0.0001
Positive TGAb, n (%) 5 (1.7) 3 (0.9) 0.99
Positive TPOAb + TGAb n (%) 15 (5.0) 3 (0.9) 0.004
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were increased in T2DM subjects’ with thyroid auto-
immunity with a 2-fold increased odds of subclinical
hyperthyroidism; (OR: 2.1 95% CI: 1.7–2.6, p <
0.0001), 1.41× increased odds of clinical hyperthyroid-
ism (OR: 1.41: 95% CI: 1.2–1.98, p < 0.0001), 3.8× in-
creased odds of subclinical hypothyroidism (OR: 3.8
95% CI: 2.7–3.8 p < 0.0001) and 61% increased odds
of clinical hypothyroidism (OR: 1.61 95% CI :1.35–
2.23, p < 0.0001).
Discussion
There are limited studies comparing autoantibody preva-
lence between T2DM subjects and controls worldwide.
Our study has shown a higher prevalence of thyroid
Table 2 Characteristics of T2DM subjects according to thyroid autoimmunity status
Variable Positive Thyroid autoimmunity Negative thyroid autoimmunity P
Number (%) 64 (21.2) 239 (78.8) <0.0001
Female Gender, n (%) 58 (70) 138 (57.7) 0.04
Age, years, (mean ± SD) 57.5 ± 9.0 57.4 ± 9.5 0.93
Duration of T2DM, median (IQR) 5 (3–10) 5 (2–10) 0.49
Systolic blood pressure, median (IQR) 140 (130–160) 139 (130–150) 0.33
Diastolic blood pressure, median (IQR) 85.5 (70–90) 80 (72–90) 0.31
Smoking, n (%) 7 (13.0) 15 (6.3) 0.27
Alcohol, n (%) 31 (48.4) 86 (36.0) 0.08
BMI, Kg/m2, median (IQR) 24.7 (24.8–30.4) 26.9 (24.5–32.1) 0.79
Waist circumference, cm, median (IQR) 99 (88–109) 95 (86–102) 0.04
Fasting blood glucose, mmol/L, median (IQR) 9.7 (8.7–11.2) 7.6 (6.7–9.4) <0.0001
HbA1c % median IQR 8.2 (6.8–9.8) 6.1 (5.2–9.6) <0.001
TC median IQR 6.03 (4.7–7.06) 4.9 (3.9–5.7) <0.001
LDL-C, mmol/L median IQR 3.87 (2.83–5.08) 2.90 (2.0–3.60) <0.0001
HDL-C, mmol/L median (IQR) 1.22 (1.0–1.45) 1.18 (1.0–1.5) 0.41
Triglycerides, mmol/L, median (IQR) 1.25 (0.99-1.67) 1.19 (0.9-1.60) 0.18
Creatinine, mmol/L, median (IQR) 84 (62–106) 77 (63–99) 0.21
TSH, pmol/L, median (IQR) 3.4 (0.1–8.1) 1.1 (0.8–1.8) <0.04
Table 3 Multiple Logistic Regression Analysis for determinants of autoimmunity in T2DM patients
Variable Unadjusted Odds ratio
95% CI




For each 10 years older 1.00 (0.88–1.15) 0.96 - -
Gender




Clinical hyperthyroidism 1.98 (1.04–3.04) <0.0001 1.41 (1.20–1.98) <0.0001
Clinical hypothyroidism 2.21 (2.11–3.41) <0.0001 1.61 (1.35–2.23) <0.0001
Subclinical hyperthyroidism 2.5 (2.19–2.90) <0.0001 2.19 (1.70–2.58) <0.0001
Subclinical hypothyroidism 5.0 (4.60–5.50) <0.0001 3.57 (2.74–3.82) <0.0001
Glycaemic state
For every 1% increase in HbA1c 1.83 (1.53–2.19) <0.0001 1.46 (1.23–1.73) <0.0001
Cholesterol status
For 1 mmol increase in total Cholesterol 1.55 (1.28–1.87) <0.0001 1.44 (1.17–1.77) 0.01
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autoimmunity in Ghanaian T2DM subjects compared to
controls with one in five T2DM subjects testing positive
for thyroid autoimmunity compared to one in twenty
seen among the controls. This finding is consistent with
those of Akbar [4], Yasmin [25] and Konstantinos [26]
who recorded significantly higher prevalence of thyroid
autoimmunity in T2DM subjects compared to controls,
with prevalence ranging between 10% and 43% among
T2DM subjects. On the contrary, Cardoso et al. [4] and
Afkhami- Ardekani et al. [22] recorded no significant
difference between the 2 groups. The discrepancy in the
results of studies investigating the prevalence of thyroid
autoimmunity in T2DM subjects may be as a result of
different methodologies employed in the determination
of autoantibodies. It has been shown that the prevalence
of these autoantibodies increases as the sensitivity of the
assay method increase. This may have accounted for the
highly significant increase in prevalence of autoantibody
prevalence seen in our study. Cardoso employed manual
ELISA methods whiles we used a more sensitive 2- site
Chemiluminescent automated method in our determin-
ation [27]. Additionally, differences in case groups, espe-
cially in terms of differing ages, race and ethnicity,
varying sample sizes, gender composition, geographic
area, duration of diabetes of subjects in the individual
studies may have accounted for the difference in results
obtained. Although not tested in our study, it has been
shown that T2DM subjects have reduced levels of Vita-
min D [28, 29], a situation that can trigger autoimmun-
ity and serve as a link between T2DM and thyroid
autoimmunity as seen in our study.
Autoimmune disorders generally, including thyroid
autoimmunity, are commonly associated with female
gender compared to males due to the role of estrogen as
an immunomodulator [29]. Additionally, there is an in-
creased susceptibility of females to antibody formation
in response to stress due to an increased T helper (Th)
2- predominant immune response compared to male
where cytotoxic response is elicited from T helper (Th)
1 response [30]. Similarly, our study found that females
T2DM subjects had a 3-fold increase risk of thyroid
autoimmunity compared to males. Our study had a sig-
nificantly higher representation of females though.
There was varying concentration of thyroid antibodies
among T2DM subjects and controls with the median
level of TPOAb significantly higher among T2DM sub-
ject compared to controls. With respect to TGAb there
was no significant difference between the two groups.
The higher levels of TPOAb may be due to the increased
stimulation of thyroid autoantibody collaborating well
with increased lymphocytic infiltration of the thyroid
gland [31].
The presence of thyroid autoimmunity was significantly
associated with subclinical thyroid disease with almost 3
fold increased risk of subclinical thyroid disease. Clinical
thyroid disease including hyperthyroidism and
hypothyroidism were also increased by about 1.5× fold in
the presence of thyroid autoimmunity. This finding sug-
gests that the presence of thyroid antibodies may serve as
an indicator of both overt and subclinical thyroid dysfunc-
tion [32, 33]. Majority of those with subclinical disease
may in the presence of thyroid autoantibodies expected to
progress to overt thyroid disease as seen in participants of
the Freemantle study [34].
In T2DM subjects with thyroid dysfunction, there is
an increase insulin resistance usually manifesting as
worsened lipid levels and poor glycemic controls [35,
36]. This is seen in our study where patient with thyroid
autoimmunity most of which was associated with thy-
roid dysfunction had an almost 2-fold higher levels of
glycated hemoglobin and dyslipidaemia. Additionally, it
has been shown that thyroid autoimmunity correlate
well with autoimmune destruction of beta- cells (though
not a significant pathophysiology in T2DM), and this
can lead to worsening of glycaemic control as seen in
our study [37].
A major limitation of this study was our inability to
test for Thyroid Stimulating Immunoglobulins which
may indicated the cause of hyperthyroidism in some of
the cases. Additionally, our inability to test for Glutamic
Acid Decarboxylase Autoantibody type 65 (GAD 65) es-
pecially in T2DM subjects in the early forties meant we
may have enrolled patients with Latent Autoimmune
Diabetes of Adults in the study. Also to be noted is our
inability to use oral glucose tolerance test in ruling out
diabetes in our controls. With this, a marginal misclassi-
fication of patients with glucose intolerance may have
been included as controls. Considering the observational
nature of this evidence and, thus, the inappropriateness
for causality inference, we advise caution in the inter-
pretation of these findings. Especially in extrapolating
these findings to different populations with different
baseline characteristics. However, the impact of these
limitations on our study findings is probably minimal,
since the discrimination between the T2DM subjects
and the control group was based on two glycemic indi-
ces (fasting glucose and HbA1c measurements), which
secured a clear distinction between groups.
The strength of this study compared to a comparable
study among West Africans is the increased sample size
of 310 T2DM subjects compared to 60 patients in the
first study. Future studies should be designed to study
the influence of other factors including Vitamin D status
on thyroid autoimmunity in T2DM subjects.
Conclusion
The results of the present study indicate that the fre-
quency of thyroid autoimmunity is significantly higher
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in Ghanaian T2DM patients, with its presence signifi-
cantly associated with thyroid dysfunction, female gen-
der, hypercholesterolemia and hyperglycemia. Therefore,
it is necessary to screen type 2 diabetes patients espe-
cially females with thyroid dysfunction for thyroid
autoimmunity.
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